Myriad Genetics (MYGN) Appoints Jan Schluchter As Chief Commercial Officer For Europe

SALT LAKE CITY and ZURICH, Switzerland, Oct. 1, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in the personalized medicine industry with innovative, high-quality molecular diagnostics, today announced that Jan Schlüchter, Ph.D., has joined the Company as chief commercial officer (CCO) of Myriad Genetics GmbH, effective Oct. 15, 2015. He will report to Gary King, executive vice president, International Operations.

"Our international business represents a significant long-term growth opportunity for Myriad and the European region is our biggest near-term opportunity," said King. "We are delighted to welcome Jan Schlüchter as our new chief commercial officer. His experience in leading and transforming healthcare businesses will help us accelerate growth internationally."

Myriad Genetics GmbH is the Zurich-based international subsidiary of Myriad Genetics, Inc. and oversees the international operations outside the United States. As the CCO, Dr. Schlüchter will lead country operations in Europe to drive new growth opportunities, offering superior molecular diagnostic solutions for patients, physicians and payors. He will focus on commercializing the Company's portfolio of hereditary cancer tests, companion diagnostics and high-value test kits.

"I am excited to be joining an organization that is passionate about helping patients make the right healthcare decisions with its pioneering molecular diagnostics," said Dr. Schlüchter. "It is an exciting time at Myriad as the company advances its pipeline and expands its commercial activities internationally. Our goal is to make new leading molecular diagnostic solutions accessible to all patients globally, and I am looking forward to working with our key stakeholders."

Dr. Schlüchter has held several senior positions at Novartis over the past 12 years. Most recently he served as Global Head of Key Account Management at Novartis' headquarters in Basel, Switzerland. Previously, he held General Management roles in Greece and Germany. Before Novartis, Dr. Schlüchter was a Consultant at McKinsey and has founded two companies. He received his master's degree in management from the University of Nuremberg, Germany and his doctor of philosophy degree in marketing from the University of Dortmund, Germany.

About Myriad Genetics GmbH

Myriad Genetics GmbH is the international subsidiary of Myriad Genetics, Inc. It has established international headquarters in Zurich, Switzerland, a full service laboratory in Munich, Germany and offices in Munich, Germany; Paris, France; Madrid, Spain; Milan, Italy; London, UK; and Zurich, Switzerland. Additionally, Myriad Genetics GmbH has a network of distributors worldwide. For more information visit:

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad is focused on strategic directives to grow existing markets, diversify through the introduction of new products, including companion diagnostics, as well as to expand internationally. For more information on how Myriad is making a difference, please visit the Company's website:

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan Lung Cancer, BRACAnalysis CDx, HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the hiring of Jan Schlüchter and the scope of his employment responsibilities; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2015, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

CONTACT: Media Contact: Ron Rogers (801) 584-3065 [email protected] Investor Contact: Scott Gleason (801) 584-1143 [email protected]